379 related articles for article (PubMed ID: 16737747)
1. Mitochondrial dynamics and disease, OPA1.
Olichon A; Guillou E; Delettre C; Landes T; Arnauné-Pelloquin L; Emorine LJ; Mils V; Daloyau M; Hamel C; Amati-Bonneau P; Bonneau D; Reynier P; Lenaers G; Belenguer P
Biochim Biophys Acta; 2006; 1763(5-6):500-9. PubMed ID: 16737747
[TBL] [Abstract][Full Text] [Related]
2. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy.
Nolli C; Goffrini P; Lazzaretti M; Zanna C; Vitale R; Lodi T; Baruffini E
Mitochondrion; 2015 Nov; 25():38-48. PubMed ID: 26455272
[TBL] [Abstract][Full Text] [Related]
3. OPA1: How much do we know to approach therapy?
Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
[TBL] [Abstract][Full Text] [Related]
4. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis.
Olichon A; Landes T; Arnauné-Pelloquin L; Emorine LJ; Mils V; Guichet A; Delettre C; Hamel C; Amati-Bonneau P; Bonneau D; Reynier P; Lenaers G; Belenguer P
J Cell Physiol; 2007 May; 211(2):423-30. PubMed ID: 17167772
[TBL] [Abstract][Full Text] [Related]
5. OPA1 (dys)functions.
Landes T; Leroy I; Bertholet A; Diot A; Khosrobakhsh F; Daloyau M; Davezac N; Miquel MC; Courilleau D; Guillou E; Olichon A; Lenaers G; Arnauné-Pelloquin L; Emorine LJ; Belenguer P
Semin Cell Dev Biol; 2010 Aug; 21(6):593-8. PubMed ID: 20045077
[TBL] [Abstract][Full Text] [Related]
6. Changes in Mitochondrial Morphology and Bioenergetics in Human Lymphoblastoid Cells With Four Novel OPA1 Mutations.
Kao SH; Yen MY; Wang AG; Yeh YL; Lin AL
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2269-78. PubMed ID: 25744979
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dynamics: to be in good shape to survive.
Herzig S; Martinou JC
Curr Mol Med; 2008 Mar; 8(2):131-7. PubMed ID: 18336293
[TBL] [Abstract][Full Text] [Related]
8. Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.
Del Dotto V; Fogazza M; Musiani F; Maresca A; Aleo SJ; Caporali L; La Morgia C; Nolli C; Lodi T; Goffrini P; Chan D; Carelli V; Rugolo M; Baruffini E; Zanna C
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3496-3514. PubMed ID: 30293569
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy.
Thiselton DL; Alexander C; Taanman JW; Brooks S; Rosenberg T; Eiberg H; Andreasson S; Van Regemorter N; Munier FL; Moore AT; Bhattacharya SS; Votruba M
Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):1715-24. PubMed ID: 12036970
[TBL] [Abstract][Full Text] [Related]
10. Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics.
Alavi MV; Fuhrmann N
Mol Neurodegener; 2013 Sep; 8():32. PubMed ID: 24067127
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.
Kushnareva Y; Seong Y; Andreyev AY; Kuwana T; Kiosses WB; Votruba M; Newmeyer DD
Cell Death Dis; 2016 Jul; 7(7):e2309. PubMed ID: 27468686
[TBL] [Abstract][Full Text] [Related]
12. Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations.
Agier V; Oliviero P; Lainé J; L'Hermitte-Stead C; Girard S; Fillaut S; Jardel C; Bouillaud F; Bulteau AL; Lombès A
Biochim Biophys Acta; 2012 Oct; 1822(10):1570-80. PubMed ID: 22800932
[TBL] [Abstract][Full Text] [Related]
13.
Cartes-Saavedra B; Lagos D; Macuada J; Arancibia D; Burté F; Sjöberg-Herrera MK; Andrés ME; Horvath R; Yu-Wai-Man P; Hajnóczky G; Eisner V
Proc Natl Acad Sci U S A; 2023 Mar; 120(12):e2207471120. PubMed ID: 36927155
[TBL] [Abstract][Full Text] [Related]
14. T-Cell Intracellular Antigens and Hu Antigen R Antagonistically Modulate Mitochondrial Activity and Dynamics by Regulating Optic Atrophy 1 Gene Expression.
Carrascoso I; Alcalde J; Sánchez-Jiménez C; González-Sánchez P; Izquierdo JM
Mol Cell Biol; 2017 Sep; 37(17):. PubMed ID: 28630277
[TBL] [Abstract][Full Text] [Related]
15. Structure, function, and regulation of mitofusin-2 in health and disease.
Chandhok G; Lazarou M; Neumann B
Biol Rev Camb Philos Soc; 2018 May; 93(2):933-949. PubMed ID: 29068134
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy.
Mayorov VI; Lowrey AJ; Biousse V; Newman NJ; Cline SD; Brown MD
BMC Biochem; 2008 Sep; 9():22. PubMed ID: 18783614
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis-like disorder in OPA1-related autosomal dominant optic atrophy.
Verny C; Loiseau D; Scherer C; Lejeune P; Chevrollier A; Gueguen N; Guillet V; Dubas F; Reynier P; Amati-Bonneau P; Bonneau D
Neurology; 2008 Mar; 70(13 Pt 2):1152-3. PubMed ID: 18287570
[No Abstract] [Full Text] [Related]
18. Mitochondrial oxidative phosphorylation compensation may preserve vision in patients with OPA1-linked autosomal dominant optic atrophy.
Van Bergen NJ; Crowston JG; Kearns LS; Staffieri SE; Hewitt AW; Cohn AC; Mackey DA; Trounce IA
PLoS One; 2011; 6(6):e21347. PubMed ID: 21731710
[TBL] [Abstract][Full Text] [Related]
19. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
[TBL] [Abstract][Full Text] [Related]
20. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.
Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V
Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
